Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cymabay Therapeutics (NQ: CBAY )

8.980 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55
Open 8.980
Bid (Size) 8.710 (1)
Ask (Size) 9.000 (1)
Prev. Close 8.980
Today's Range 8.980 - 8.980
52wk Range 1.810 - 11.22
Shares Outstanding 84,677,939
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... 
Via Benzinga
Why CymaBay Therapeutics Stock Nose-Dived This Week
Investors did not warmly greet the latest news from the biotech. 
Via The Motley Fool

Performance

YTD
+50.67%
+50.67%
1 Month
-17.08%
-17.08%
3 Month
+9.78%
+9.78%
6 Month
+165.68%
+165.68%
1 Year
+358.16%
+358.16%

More News

Read More
Expert Ratings for CymaBay Therapeutics
Via Benzinga
CymaBay Therapeutics: Q1 Earnings Insights
Via Benzinga
CymaBay Therapeutics's Earnings Outlook
Via Benzinga
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 5/9
Via Investor Brand Network
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 5/2
Via Investor Brand Network
The Latest Analyst Ratings for CymaBay Therapeutics
Via Benzinga
Analyst Ratings for CymaBay Therapeutics
Via Benzinga
Preview: CymaBay Therapeutics's Earnings
Via Benzinga
Analyst Expectations for CymaBay Therapeutics's Future
Via Benzinga
Four Potential Breakout Stocks For The Rest Of The Week
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023
Via Benzinga
Analyst Expectations for CymaBay Therapeutics's Future
Via Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why CymaBay Therapeutics Shares Are Rising
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
5 Most Expensive Health Care Stocks You Should Worry About
Via Benzinga
CymaBay Therapeutics: Q2 Earnings Insights
Via Benzinga
Earnings Outlook For CymaBay Therapeutics
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Via Benzinga
79 Biggest Movers From Yesterday
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.